SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MYOKMyoKardia, Inc. 0.09%223.531.8%$529.51m
HZNPHorizon Therapeutics Plc -3.59%74.935.8%$156.10m
VRXValeant Pharmaceuticals International, Inc. -2.08%16.5014.1%$97.09m
JAZZJazz Pharmaceuticals Plc -1.05%144.102.4%$73.67m
CTLTCatalent, Inc. -1.80%87.782.1%$69.26m
UTHRUnited Therapeutics Corp. 3.06%134.2314.1%$68.71m
BHCBausch Health Cos., Inc. -2.08%16.500.0%$59.77m
SAGESAGE Therapeutics, Inc. -0.72%73.388.6%$45.85m
ICLRICON plc -1.62%180.304.2%$42.06m
ARGXargenx SE -2.46%248.130.0%$35.01m
PRGOPerrigo Co. Plc 3.08%43.846.8%$32.61m
ENDPEndo International Plc -3.38%4.578.7%$30.02m
GWPHGW Pharmaceuticals Plc 0.76%90.016.2%$28.78m
AMRNAmarin Corp. Plc -1.22%4.861.5%$26.85m
ICPTIntercept Pharmaceuticals, Inc. -3.97%27.7916.8%$23.24m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.